14.50
-0.1(-0.68%)
Currency In USD
| Previous Close | 14.6 |
| Open | 14.67 |
| Day High | 14.67 |
| Day Low | 14.42 |
| 52-Week High | 15 |
| 52-Week Low | 6.69 |
| Volume | 1.41M |
| Average Volume | 2.45M |
| Market Cap | 4.56B |
| PE | 1,450 |
| EPS | 0.01 |
| Moving Average 50 Days | 13.22 |
| Moving Average 200 Days | 10.19 |
| Change | -0.1 |
If you invested $1000 in Amneal Pharmaceuticals, Inc. (AMRX) since IPO date, it would be worth $966.02 as of February 21, 2026 at a share price of $14.5. Whereas If you bought $1000 worth of Amneal Pharmaceuticals, Inc. (AMRX) shares 5 years ago, it would be worth $2,705.22 as of February 21, 2026 at a share price of $14.5.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Amneal Pharmaceuticals Added to S&P SmallCap 600® Index
GlobeNewswire Inc.
Jan 28, 2026 9:05 PM GMT
BRIDGEWATER, N.J., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”) today announced that it has been added to the S&P SmallCap 600® Index. The inclusion will become effective prior to the ope
Amneal to Report Fourth Quarter and Full Year 2025 Results on February 27, 2026
GlobeNewswire Inc.
Jan 27, 2026 1:00 PM GMT
BRIDGEWATER, N.J., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) (“Amneal” or the “Company”), today announced that the Company will release its fourth quarter and full year 2025 financial results on Friday, February
Amneal Announces FDA Approval of Denosumab Biosimilars Referencing Prolia® and XGEVA®
GlobeNewswire Inc.
Dec 22, 2025 9:01 PM GMT
Approvals expand Amneal’s biosimilars portfolioCompany expects to commercialize six biosimilars across eight presentations by 2027 BRIDGEWATER, N.J., Dec. 22, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) (NASDAQ